Ziccum AB: senior Astra Zeneca vaccine & biopharmaceutical strategist to be new Board member
Few people know the special risks and rewards of working with vaccines and biopharmaceuticals better than Astra Zeneca’s VP Mikaela Bruhammar. From 2012-2015 she led the team that launched and grew Astra Zeneca’s unique inhalable LAIV flu vaccine in Europe and US. Now she will bring her biologics/ vaccine expertise and broad pharma commercial experience to the Board of Ziccum AB. She will be proposed as new Board Member at the company’s Annual General Meeting on May 20.“The rewards can be great, but the risks can too. Vaccines aren’t like other pharmaceuticals. For some companies they can